Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation

Clinical Cancer Research

Volumn 15, Issue 9, 2009, Pages 3118-3125

  Hillengass, Jens ^a,b   Zechmann, Christian ^a   Bäuerle, Tobias ^a   Wagner Gund, Barbara ^b   Heiss, Christiane ^a,b   Benner, Axel ^a   Ho, Anthony ^b   Neben, Kai ^b   Hose, Dirk ^b   Kauczor, Hans Ulrich ^b   Goldschmidt, Hartmut ^a,b   Delorme, Stefan ^a   Moehler, Thomas ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMACYTOSIS; PRIORITY JOURNAL; PROGNOSIS;

BONE MARROW; CASE-CONTROL STUDIES; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MICROCIRCULATION; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PLASMA CELLS; PROGNOSIS;

EID: 65649104694     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2310     Document Type: Article

References (36)

1. Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 1972; 40:719-724
2. Axelsson U, Bachmann R, Hallen J. Frequency of pathological proteins (M-components) from 6,995 sera from an adult population. Acta Med Scand 1966; 179:235-247
3. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007;82:323-341 (Pubitemid 46348934)
4. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564-569
5. Bernasconi P, Cavigliano PM, Boni M, et al. Long-term follow up with conventional cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significance. Br J Haematol 2002;118: 545-549
6. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001;28: 565-569 (Pubitemid 33134415)
7. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003;45:227-244 (Pubitemid 36299132)
8. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61. (Pubitemid 19115892)
9. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006;5:1779-1787 (Pubitemid 44435320)
10. Jackson A, O'ConnorJP, Parker GJ, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007;13:3449-3459 (Pubitemid 46955104)
11. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003;17: 509-520 (Pubitemid 36528666)
12. Rahmouni A, Divine M, Mathieu D, et al. Detection of multiple myeloma involving the spine: efficacy of fat-suppression and contrast-enhanced MR imaging. AJR Am J Roentgenol 1993;160:1049-1052
13. Brix G , Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd- DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15:621-628
14. Moehler TM, Hawighorst H, Neben K, et al. Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. Int J Cancer 2001;93:862-868
15. Nosas-Garcia S, Moehler T, Wasser K, et al. Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers. J Magn Reson Imaging 2005;22:154-162
16. Hillengass J, Wasser K, Delorme S, et al. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma. Clin Cancer Res 2007;13:475-481
17. Scherer A, Wittsack HJ, Strupp C, Gattermann N, Haas R, Modder U. Vertebral fractures in multiple myeloma: first results of assessment of fracture risk using dynamic contrast-enhanced magnetic resonance imaging. Ann Hematol 2002;81:517-521 (Pubitemid 36075504)
18. Greipp PR. Smoldering, asymptomatic stage 1, and indolent myeloma. Curr Treat Options Oncol 2000;1: 119-126
19. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757
20. Brix G, Schreiber W, Hoffmann U, Guckel F, Hawighorst H, Knopp MV. Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography. Radiologe 1997; 37:470-480
21. Hawighorst H, Knapstein PG, Weikel W, et al. Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 1997;57: 4777-4786
22. Rahmouni A, Montazel JL, Divine M, et al. Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging. Radiology 2003;229:710-717
23. Rahmouni A, Divine M, Mathieu D, et al. MR appearance of multiple myeloma of the spine before and after treatment. AJR Am J Roentgenol 1993;160: 1053-1057
24. Garewal H, Durie BG, Kyle RA, Finley P, Bower B, Serokman R. Serum β 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol 1984;2:51-57 (Pubitemid 14165796)
25. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika 1982;3: 553-566
26. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965;1-2:203-223
27. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. Journal of the Royal Statistical Society 1972;135:185-207.
28. Holm S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 1979;6: 65-70.
29. Stabler A, Baur A, Bartl R, Munker R, Lamerz R, Reiser MF. Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol 1996;167:1029-1036 (Pubitemid 26322270)
30. Hillengass J, Zechmann CM, Nadler A, et al. Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma. Int J Cancer 2008;122:2871-2875
31. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002;20: 1625-1634
32. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stagemyeloma. Leukemia 2003;17:775-779
33. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364 (Pubitemid 26272076)
34. Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004;104:1159-1165 (Pubitemid 39108790)
35. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8:2210-2216
36. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-508